Elicio Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ELTX | HBP.TO | CVM | EVAX | DTC.CN | ANIX | |
|---|---|---|---|---|---|---|
| Market cap | 42.26M | 70.27M | 24.27M | 26.79M | 25.50M | 114.03M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.9 | -8.4 | -0.2 | -198.0 | — | -10.6 |
| Price/book | 4.3 | 4.8 | 2.2 | 2.6 | 7.3 | 7.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −83.35% | −54.68% | −79.22% | −52.56% | −61.05% | −24.82% |
| Today | +2.63% | 0.00% | −2.13% | +0.34% | −1.47% | +7.36% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ELTX news ›Elicio Therapeutics to Host Virtual KOL Event on November 11, 2026: ELI-002 7P for Metastatic and Neoadjuvant PDAC
November 04, 2026 08:00 ET | Source: Elicio Therapeutics Inc. Elicio Therapeutics Inc. The event will feature expert oncologists Eileen M. O’Reilly, MD, FASCO and Kevin C. Soares, MD, both of Memorial Sloan Kettering Cancer Center…
Elicio Therapeutics to Present Phase 2 AMPLIFY-7P Results at the SITC 2026 Annual Meeting
Title: Updates on Clinical Results from the AMPLIFY-7P Study of a Lymph Node-Targeted KRAS Vaccine Presenter: Darrell J. Irvine, PhD, The Scripps Research Institute Session Number/Name: 103: Thomas Waldmann Memorial Plenary Session: Cancer…
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
Baseline Prognostic Imbalance Provides Important Context for ITT Results Early DFS Separation and Immune Findings Support Further Evaluation About the AMPLIFY-7P Phase 2 Study AMPLIFY-7P Phase 2 is a randomized study evaluating camupepimut…
From the 4Search news index, newest first.